Biogen earnings were $1.6B for the trailing 12 months ending Dec 31, 2024, with 39.8% growth year over year. The latest BIIB earnings report on Dec 31, 2024 announced Q4 2024 earnings of $266.7M, down 31.4% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIIB reported annual earnings of $1.6B, with 40.6% growth.
BIIB past earnings growth
How has BIIB's earnings growth performed historically?
On BIIB's earnings call on Invalid Date, Biogen (NASDAQ: BIIB) reported Q4 2024 earnings per share (EPS) of $1.83, up 6.4% year over year. Total BIIB earnings for the quarter were $266.70 million. In the same quarter last year, Biogen's earnings per share (EPS) was $1.72.
As of the last Biogen earnings report, Biogen is currently profitable. Biogen's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $1.63 billion, a 40.57% increase year over year.
What was BIIB's earnings growth in the past year?
As of Biogen's earnings date in Invalid Date, Biogen's earnings has grown 39.78% year over year. This is 327.82 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 367.59%. BIIB earnings in the past year totalled $1.63 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.